Ajay K. Singh, M.B.,B.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematinics | 46 | 2023 | 282 | 11.820 |
Why?
|
| Anemia | 54 | 2022 | 1516 | 7.530 |
Why?
|
| Erythropoietin | 39 | 2023 | 718 | 7.450 |
Why?
|
| Renal Insufficiency, Chronic | 34 | 2024 | 2297 | 4.870 |
Why?
|
| Hemoglobins | 43 | 2023 | 1531 | 4.800 |
Why?
|
| Renal Dialysis | 34 | 2023 | 1789 | 3.130 |
Why?
|
| Kidney Diseases | 23 | 2019 | 2100 | 2.710 |
Why?
|
| Kidney Failure, Chronic | 27 | 2017 | 2493 | 2.540 |
Why?
|
| Epoetin Alfa | 19 | 2022 | 78 | 2.250 |
Why?
|
| Barbiturates | 5 | 2023 | 113 | 1.790 |
Why?
|
| Glycine | 4 | 2024 | 672 | 1.400 |
Why?
|
| Anemia, Iron-Deficiency | 5 | 2013 | 372 | 1.230 |
Why?
|
| Diabetic Nephropathies | 6 | 2024 | 973 | 1.120 |
Why?
|
| Nephrology | 4 | 2019 | 270 | 0.850 |
Why?
|
| Recombinant Proteins | 22 | 2022 | 6512 | 0.800 |
Why?
|
| Kidney | 10 | 2019 | 7057 | 0.800 |
Why?
|
| Iron | 6 | 2022 | 1813 | 0.680 |
Why?
|
| Ferritins | 6 | 2017 | 600 | 0.660 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 8055 | 0.660 |
Why?
|
| Bone Diseases, Metabolic | 3 | 2016 | 411 | 0.580 |
Why?
|
| Benzhydryl Compounds | 2 | 2024 | 943 | 0.560 |
Why?
|
| Iron Compounds | 2 | 2008 | 28 | 0.560 |
Why?
|
| Lupus Nephritis | 3 | 2005 | 327 | 0.520 |
Why?
|
| Proteinuria | 4 | 2013 | 610 | 0.450 |
Why?
|
| Hypertension, Renal | 1 | 2014 | 135 | 0.450 |
Why?
|
| Certification | 2 | 2019 | 420 | 0.440 |
Why?
|
| Renal Replacement Therapy | 2 | 2015 | 282 | 0.430 |
Why?
|
| Pathology | 1 | 2016 | 270 | 0.420 |
Why?
|
| Chronic Disease | 16 | 2010 | 9384 | 0.410 |
Why?
|
| Mass Screening | 3 | 2014 | 5455 | 0.400 |
Why?
|
| Ferric Compounds | 3 | 2008 | 377 | 0.390 |
Why?
|
| Humans | 111 | 2024 | 768887 | 0.390 |
Why?
|
| United States Food and Drug Administration | 3 | 2010 | 1672 | 0.390 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2008 | 27 | 0.380 |
Why?
|
| Fanconi Syndrome | 1 | 2011 | 35 | 0.380 |
Why?
|
| Ventricular Fibrillation | 1 | 2014 | 537 | 0.370 |
Why?
|
| Saudi Arabia | 5 | 2016 | 212 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 12252 | 0.360 |
Why?
|
| Intention to Treat Analysis | 2 | 2021 | 417 | 0.350 |
Why?
|
| Glomerular Filtration Rate | 8 | 2016 | 2228 | 0.350 |
Why?
|
| Occupational Exposure | 1 | 2020 | 1807 | 0.340 |
Why?
|
| Kidney Tubules | 2 | 2009 | 454 | 0.340 |
Why?
|
| Injections, Subcutaneous | 3 | 2010 | 687 | 0.340 |
Why?
|
| Calcium Compounds | 1 | 2009 | 40 | 0.320 |
Why?
|
| Cardiovascular Diseases | 15 | 2022 | 15662 | 0.320 |
Why?
|
| Biliary Tract Diseases | 1 | 2010 | 159 | 0.320 |
Why?
|
| Platelet Activation | 1 | 2012 | 644 | 0.310 |
Why?
|
| Middle Aged | 45 | 2022 | 223740 | 0.300 |
Why?
|
| Transferrin | 3 | 2008 | 284 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3253 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2010 | 10397 | 0.290 |
Why?
|
| Minerals | 1 | 2009 | 282 | 0.290 |
Why?
|
| Vitamin D | 3 | 2013 | 3311 | 0.280 |
Why?
|
| Male | 56 | 2022 | 365249 | 0.270 |
Why?
|
| Nephritis, Interstitial | 2 | 2008 | 158 | 0.270 |
Why?
|
| Kidney Glomerulus | 1 | 2009 | 569 | 0.270 |
Why?
|
| Acute Kidney Injury | 3 | 2014 | 1936 | 0.270 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2009 | 336 | 0.250 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 1568 | 0.250 |
Why?
|
| Female | 55 | 2022 | 397464 | 0.250 |
Why?
|
| India | 3 | 2020 | 2325 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2010 | 3709 | 0.250 |
Why?
|
| Prevalence | 10 | 2016 | 15875 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 7 | 2012 | 7460 | 0.240 |
Why?
|
| Societies, Medical | 2 | 2019 | 3967 | 0.240 |
Why?
|
| Treatment Outcome | 23 | 2022 | 65485 | 0.240 |
Why?
|
| Aged | 37 | 2022 | 171790 | 0.240 |
Why?
|
| Phosphates | 1 | 2008 | 765 | 0.230 |
Why?
|
| Erythropoiesis | 2 | 2023 | 693 | 0.230 |
Why?
|
| Reimbursement Mechanisms | 1 | 2010 | 677 | 0.230 |
Why?
|
| Research Design | 5 | 2024 | 6213 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2014 | 1959 | 0.230 |
Why?
|
| Injections, Intravenous | 5 | 2008 | 1379 | 0.220 |
Why?
|
| Heart Arrest | 1 | 2014 | 1515 | 0.220 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2422 | 0.220 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1388 | 0.220 |
Why?
|
| Nurse's Role | 1 | 2005 | 188 | 0.220 |
Why?
|
| Heart Failure | 10 | 2024 | 11879 | 0.220 |
Why?
|
| Risk Factors | 20 | 2020 | 74971 | 0.220 |
Why?
|
| Early Diagnosis | 3 | 2014 | 1195 | 0.220 |
Why?
|
| Cytokines | 2 | 2008 | 7453 | 0.210 |
Why?
|
| Drug Approval | 1 | 2010 | 820 | 0.210 |
Why?
|
| Cost Savings | 1 | 2008 | 915 | 0.210 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 1761 | 0.210 |
Why?
|
| Kidney Transplantation | 3 | 2009 | 4265 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1737 | 0.200 |
Why?
|
| Ibuprofen | 1 | 2003 | 229 | 0.200 |
Why?
|
| Glomerulonephritis | 1 | 2004 | 333 | 0.200 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 806 | 0.200 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2016 | 124 | 0.200 |
Why?
|
| Pandemics | 1 | 2022 | 8745 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2010 | 1162 | 0.190 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 797 | 0.190 |
Why?
|
| Granuloma | 1 | 2003 | 329 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2010 | 1305 | 0.190 |
Why?
|
| Blood Platelets | 1 | 2012 | 2479 | 0.190 |
Why?
|
| Stroke | 9 | 2021 | 9756 | 0.190 |
Why?
|
| Testis | 1 | 2004 | 784 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 10778 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2007 | 1320 | 0.170 |
Why?
|
| Endoscopy | 1 | 2010 | 1862 | 0.170 |
Why?
|
| Prognosis | 8 | 2016 | 30044 | 0.170 |
Why?
|
| Albuminuria | 1 | 2023 | 658 | 0.170 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1627 | 0.170 |
Why?
|
| Ovary | 1 | 2004 | 965 | 0.170 |
Why?
|
| Tobacco, Smokeless | 1 | 2020 | 133 | 0.160 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2001 | 167 | 0.160 |
Why?
|
| Fertility | 1 | 2004 | 770 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2008 | 1597 | 0.160 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 11521 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 684 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2714 | 0.150 |
Why?
|
| Glucosides | 1 | 2023 | 533 | 0.150 |
Why?
|
| Risk Assessment | 11 | 2019 | 24330 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2009 | 2589 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 2227 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2010 | 2403 | 0.150 |
Why?
|
| Medicare | 4 | 2010 | 6888 | 0.140 |
Why?
|
| Infertility | 1 | 2004 | 654 | 0.140 |
Why?
|
| Hypertension | 4 | 2013 | 8615 | 0.140 |
Why?
|
| Contrast Media | 2 | 2008 | 5334 | 0.140 |
Why?
|
| Adult | 23 | 2023 | 223818 | 0.140 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 15471 | 0.140 |
Why?
|
| Hematocrit | 2 | 2009 | 623 | 0.140 |
Why?
|
| Patients | 1 | 2023 | 908 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4428 | 0.130 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 377 | 0.130 |
Why?
|
| Biopsy | 5 | 2019 | 6805 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 2194 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2014 | 5369 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2012 | 2931 | 0.120 |
Why?
|
| Neoplasms | 2 | 2023 | 22390 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2010 | 2339 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2003 | 2382 | 0.110 |
Why?
|
| International Cooperation | 2 | 2019 | 1436 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 5195 | 0.110 |
Why?
|
| Blood Viscosity | 1 | 2013 | 125 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 3200 | 0.100 |
Why?
|
| Age Factors | 4 | 2020 | 18454 | 0.100 |
Why?
|
| Data Collection | 1 | 2022 | 3322 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 4207 | 0.100 |
Why?
|
| Middle East | 1 | 2012 | 233 | 0.100 |
Why?
|
| United States | 10 | 2017 | 73180 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2012 | 15955 | 0.100 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 684 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 26384 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2231 | 0.090 |
Why?
|
| Metformin | 1 | 2019 | 909 | 0.090 |
Why?
|
| Double-Blind Method | 8 | 2022 | 12469 | 0.090 |
Why?
|
| Electric Countershock | 1 | 2014 | 534 | 0.090 |
Why?
|
| Comorbidity | 3 | 2013 | 10591 | 0.090 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 161 | 0.090 |
Why?
|
| CD40 Ligand | 1 | 2012 | 528 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2010 | 4148 | 0.080 |
Why?
|
| Program Development | 1 | 2016 | 1300 | 0.080 |
Why?
|
| Drug Costs | 2 | 2008 | 1198 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2006 | 965 | 0.080 |
Why?
|
| P-Selectin | 1 | 2012 | 599 | 0.080 |
Why?
|
| Iron, Dietary | 1 | 2010 | 148 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 455 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 2171 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2010 | 122 | 0.080 |
Why?
|
| Cilazapril | 1 | 2008 | 3 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2022 | 54950 | 0.080 |
Why?
|
| Risk Reduction Behavior | 3 | 2011 | 1119 | 0.080 |
Why?
|
| Ferrosoferric Oxide | 1 | 2010 | 348 | 0.080 |
Why?
|
| Survival Rate | 3 | 2014 | 12873 | 0.080 |
Why?
|
| Inflammation | 1 | 2008 | 10869 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2008 | 61 | 0.080 |
Why?
|
| Ergocalciferols | 1 | 2009 | 110 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 59 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 353 | 0.070 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 2560 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2013 | 2280 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 3858 | 0.070 |
Why?
|
| Publication Bias | 1 | 2008 | 159 | 0.070 |
Why?
|
| Sclerosis | 1 | 2008 | 212 | 0.070 |
Why?
|
| Cardiac Output | 1 | 2010 | 838 | 0.070 |
Why?
|
| Phosphorus | 1 | 2009 | 336 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 4045 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 13317 | 0.070 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2014 | 1024 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3438 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2010 | 250 | 0.070 |
Why?
|
| Calcitriol | 1 | 2009 | 303 | 0.070 |
Why?
|
| Age Distribution | 1 | 2013 | 2875 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 363 | 0.070 |
Why?
|
| Organotechnetium Compounds | 1 | 2007 | 133 | 0.070 |
Why?
|
| Models, Biological | 1 | 2003 | 9499 | 0.070 |
Why?
|
| Polycythemia | 1 | 2008 | 124 | 0.070 |
Why?
|
| Patient Selection | 2 | 2010 | 4265 | 0.070 |
Why?
|
| Biological Availability | 1 | 2007 | 392 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2008 | 182 | 0.070 |
Why?
|
| Leuprolide | 1 | 2008 | 313 | 0.070 |
Why?
|
| Half-Life | 1 | 2007 | 651 | 0.070 |
Why?
|
| Disease Progression | 4 | 2017 | 13677 | 0.070 |
Why?
|
| Awareness | 1 | 2010 | 653 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2014 | 997 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2010 | 4053 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2009 | 10115 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2007 | 2734 | 0.060 |
Why?
|
| Histology | 1 | 2004 | 16 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 313 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2008 | 705 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2016 | 81892 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2007 | 411 | 0.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 291 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2008 | 552 | 0.060 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 279 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 1498 | 0.060 |
Why?
|
| Iothalamic Acid | 1 | 2003 | 18 | 0.060 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2003 | 67 | 0.060 |
Why?
|
| Prednisone | 1 | 2008 | 1567 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2012 | 6346 | 0.060 |
Why?
|
| Nephrosis | 1 | 2003 | 43 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 436 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 13020 | 0.050 |
Why?
|
| Bone Diseases | 1 | 2007 | 416 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2011 | 2709 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6546 | 0.050 |
Why?
|
| Ovum | 1 | 2004 | 187 | 0.050 |
Why?
|
| Leiomyoma | 1 | 2008 | 644 | 0.050 |
Why?
|
| Probability | 1 | 2008 | 2483 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2008 | 949 | 0.050 |
Why?
|
| Adolescent | 6 | 2016 | 89247 | 0.050 |
Why?
|
| Nephritis | 1 | 2003 | 147 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 732 | 0.050 |
Why?
|
| Curriculum | 1 | 2016 | 3782 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1629 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 812 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2012 | 2597 | 0.050 |
Why?
|
| Cell Transplantation | 1 | 2004 | 475 | 0.050 |
Why?
|
| Sirolimus | 1 | 2009 | 1540 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2014 | 4541 | 0.050 |
Why?
|
| Sex Factors | 2 | 2013 | 10641 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2008 | 6320 | 0.050 |
Why?
|
| Reference Values | 2 | 2013 | 4941 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 1514 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2014 | 41800 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 59738 | 0.050 |
Why?
|
| Quality of Life | 4 | 2023 | 13510 | 0.050 |
Why?
|
| Algorithms | 3 | 2012 | 14199 | 0.050 |
Why?
|
| Morbidity | 1 | 2006 | 1757 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2001 | 72 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 1724 | 0.050 |
Why?
|
| Health Care Reform | 1 | 2010 | 1262 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2008 | 895 | 0.040 |
Why?
|
| Calcium | 2 | 2016 | 5792 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2014 | 6413 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2009 | 2421 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2008 | 1187 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2010 | 8742 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2004 | 631 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1535 | 0.040 |
Why?
|
| Risk | 2 | 2010 | 9621 | 0.040 |
Why?
|
| Young Adult | 4 | 2017 | 60110 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 1034 | 0.040 |
Why?
|
| Thrombosis | 2 | 2006 | 2956 | 0.040 |
Why?
|
| Hospitalization | 3 | 2009 | 10845 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 4835 | 0.040 |
Why?
|
| Calcinosis | 1 | 2008 | 1481 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1893 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 904 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2010 | 5323 | 0.040 |
Why?
|
| Oocytes | 1 | 2004 | 1172 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2004 | 733 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 3985 | 0.040 |
Why?
|
| Causality | 1 | 2005 | 1255 | 0.040 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 12093 | 0.040 |
Why?
|
| Nucleosomes | 1 | 2002 | 492 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2004 | 1676 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2008 | 3233 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2007 | 2059 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2016 | 42684 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 11119 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2017 | 134 | 0.040 |
Why?
|
| Length of Stay | 2 | 2014 | 6525 | 0.040 |
Why?
|
| Acute Disease | 1 | 2008 | 7245 | 0.040 |
Why?
|
| Child | 4 | 2016 | 80969 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 1470 | 0.040 |
Why?
|
| Incidence | 2 | 2012 | 21545 | 0.040 |
Why?
|
| Developing Countries | 1 | 2009 | 2906 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4356 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2009 | 9682 | 0.030 |
Why?
|
| Cause of Death | 2 | 2019 | 3721 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 39394 | 0.030 |
Why?
|
| Inpatients | 1 | 2008 | 2570 | 0.030 |
Why?
|
| Massachusetts | 1 | 2009 | 8888 | 0.030 |
Why?
|
| Education, Distance | 1 | 2019 | 260 | 0.030 |
Why?
|
| Oliguria | 1 | 2014 | 20 | 0.030 |
Why?
|
| Medicaid | 1 | 2008 | 2843 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2008 | 4492 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2010 | 4859 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22294 | 0.030 |
Why?
|
| Tuberculosis | 1 | 2007 | 2029 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 20776 | 0.030 |
Why?
|
| Creatinine | 2 | 2009 | 1917 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2002 | 2126 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 12563 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 40266 | 0.030 |
Why?
|
| Hemoglobinometry | 1 | 2012 | 35 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2013 | 315 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7472 | 0.020 |
Why?
|
| Diuretics | 1 | 2014 | 614 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 5892 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 14751 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 948 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 1803 | 0.020 |
Why?
|
| Thailand | 1 | 2009 | 288 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 1820 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13699 | 0.020 |
Why?
|
| Mortality | 1 | 2019 | 2915 | 0.020 |
Why?
|
| Triglycerides | 1 | 2015 | 2464 | 0.020 |
Why?
|
| Animals | 2 | 2009 | 169408 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9528 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 2402 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 963 | 0.010 |
Why?
|
| Executive Function | 1 | 2013 | 1405 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2006 | 585 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6242 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 2724 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2008 | 1421 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 2007 | 408 | 0.010 |
Why?
|
| Memory | 1 | 2013 | 2210 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 1998 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5890 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1643 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2238 | 0.010 |
Why?
|
| Sepsis | 1 | 2014 | 2609 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1669 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9375 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7148 | 0.010 |
Why?
|
| Disease Management | 1 | 2009 | 2537 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2006 | 2783 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2007 | 2396 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14795 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 36541 | 0.010 |
Why?
|